Market Analysis — RIVERVIEW MEDICAL CENTER
NJ market | 5 hospitals | HHI: 3,850 (Concentrated)
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
5
Hospitals in Market
1,346
Total Beds
$2.1B
Market Revenue
Concentrated
HHI: 3,850
None
Moat Rating (4/10)
#2
Market Share Rank
Competitive Moat (Mauboussin Framework)
Based on "Measuring the Moat" adapted for healthcare. Score 0-10: wide (8+), narrow (5-7), none (<5).
Scale Advantageweak
Switching Costshigh
Market Share17.8%
Top 3 Concentration89.5%
Network Density0.37
Margin vs Market-0.0%
Bed Util vs Market-8.1%
What This Means
This hospital has a none moat — no moat — commoditized market position, pricing power limited. The NJ market is highly concentrated — few dominant players, potential antitrust concerns (HHI: 3,850).
Implications: Operational improvements are the primary value driver — see the EBITDA bridge. Compare against peers via comparables or see the full NJ market.
Top Competitors
| Hospital | Beds | Revenue | Rev Share | Bed Share |
|---|---|---|---|---|
| JERSEY SHORE UNIVERSITY MED CTR | 604 | $1,168M | 56.8% | 44.9% |
| CENTRASTATE MEDICAL CENTER | 240 | $308M | 15.0% | 17.8% |
| BAYSHORE MEDICAL CENTER | 175 | $187M | 9.1% | 13.0% |
| ENCOMPASS HEALTH REHABILITATION HOSP | 60 | $29M | 1.4% | 4.5% |
Regional Payer Mix
■ Medicare 48%■ Medicaid 3%■ Commercial 49%